Mikhail Blagosklonny, a scientist, researcher, professor of oncology, and a leading advanced researcher in the field of oncology. Blagosklonny is also an authority in the treatment of cancer and aging.
Waging War On Cancer
Mikhail Blagosklonny is known as “The Man Waging War Against Cancer and Aging.” As a scientist and researcher, he has spent thousands of hours on his quest advancing the treatment for cancer cures. Along with this line, follows his interest in the aging process and the causes of the breakdown of cells and what can be done in continuing a healthy life through the aging process.
Endeavors From Graduation to Present
Currently working at Roswell Park Cancer Institute, in the Department of Cell Stress Biology, Blagosklonny enthusiastically searches for the answers to cancer and its treatment. Blagosklonny holds a Ph.D. in experimental medicine that he received from the First Pavlov State Medical University in St. Peterburg. In 2002 Mikhail Blagosklonny acquired his associate professor of Medicine while working at the New York Medical College in Valhalla, and went on to work at Ordway Research Institute in Albany, NY as a senior scientist.
Oncologies Shining Star
Research and the publication of articles filled with information and findings of years of work as a scientist, Blagosklonny has been a shining star in the oncology field. The doctor is also famous for the popular drug in the treatment of aging called Rapamycin. He is touted as being the most committed advocate for Rapamycin used in the research of aging.
Delving Into Research
The research enthusiast is also well-known for his research in ontogenesis, single transduction, cell cycle, mitosis, anticancer, tumor suppressor and anticancer therapeutics. Many of his writings include studies about chemotherapeutic engineering and cell psychotherapy.Other publications include Anti-aging Drug Today, Lifespan Extension and Cancer Prevention in HER-2/neu Transgenic Mice, Immunosuppressants in Cancer Prevention and Therapy, and much more.
Want To Know More About Mikhail Blagosklonny?
For more information on Mikhail Blagosklonny’s role played in advancing the research on cancer and aging through his focus on Rapamycin (THOR). You may also follow Mikhail Blagosklonny.
Mikhail Blagosklonny also serves as RKOCU and Editor-in-Chief, Oncotarget. Oncotarget is an open-access medical journal. This journal is a peer-reviewed document released weekly covering all aspects of oncology. This journal has been existence since 2010 with the primary editors being Mikhail Blagosklonny and Andrei V. Gudkov. This peer-review is an insightful research document, and the information it releases is gaining in popularity. With its growth in popularity, the Oncotarget Journal will now be released twice weekly, on Tuesday and Friday.Oncotarget has been in the news more frequently due to information released on Gallbladder Tumor Growth, Cannabis as a possible preventive use against developing cancer, neurodegenerative disease, Alzheimer’s and arthritis. In previous issues of the journal, you can find articles on Immunology and Microbiology, Chromosome, Pathology Beyond Oncology, and more.Be prepared for a phenomenal scientific review of the latest in cancer research and the aging process.